Clinical practice drives marimastat deal

In a move to secure a position in Japan's market for cancer drugs, Tanabe Seiyaku Co. Ltd. (Osaka, Japan) sealed a deal potentially worth $74 million to develop and market British Biotech plc's marimastat oral anti-cancer matrix metalloproteinase inhibitor in Japan.

According to James Noble, BBIOY's finance director, Tanabe's willingness to pay so much for a single country deal was predicated in part on marimastat's fit into the Japanese way of thinking about cancer treatment